ClinicalTrials.gg
Not yet recruitingNCT07929805Updated Nov 10, 2026

ACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase Ib

A Phase 1 interventional study of ACT201 Injection and ACT201 Injection in Chronic Hepaititis B, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Not yet recruiting at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Nov 10, 2026Newly registeredGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a multicenter, randomized, open-label, parallel-controlled Phase Ib clinical trial. It aims to evaluate the safety and preliminary efficacy of ACT201 Injection combined with standard therapy (PegIFNα, NA) in participants with chronic hepatitis B who are receiving NA treatment. A total of 40 participants with chronic hepatitis B will be enrolled. Eligible participants should have stable NA treatment, HBV DNA \< 100 IU/mL, negative HBeAg, and HBsAg ≤ 100 IU/mL. They will be randomized into four treatment groups at a 1:1:1:1 ratio.

02

Conditions studied

  • Chronic Hepaititis B

Keywords

  • Chronic Hepaititis B
  • ACT201 Injection
  • PegIFNα-2b Injection
03

In context

Lead sponsor

Xiamen Amoytop Biotech Co., Ltd. is the lead sponsor of 32 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in this trial and sign the form;
  • Aged 18 to 65 years (inclusive), male or female;
  • (BMI) ranging from 18 to 32 kg/m² (inclusive);
  • -positive or HBV DNA-positive for at least 6 months, or with prior liver results consistent with chronic HBV infection, or HBsAg-positive and anti-HBc IgM-negative at screening;
  • Receiving stable nucleos(t)ide analogue (NA) therapy at screening;
  • Meeting the specified requirements for HBsAg, HBeAg, HBV DNA and liver function parameters;
  • Willing to use effective with no plan to conceive, donate sperm or donate ova.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have sustained major trauma or undergone major surgery recently, or have a planned surgery;
  • Subjects with uncontrolled, abnormalities or other severe illnesses in addition to chronic infection;
  • Subjects with a history of other liver diseases;
  • Subjects with a history of liver cirrhosis;
  • Subjects with imaging findings suggestive of a suspected malignant hepatic lesion;
  • Subjects with prior or current manifestations of hepatic decompensation;
  • Subjects with a history of extrahepatic diseases potentially associated with HBV immune status;
  • Subjects with other diseases associated with vasculitis;
  • Subjects with infections (other than HBV) requiring systemic antiviral or antibacterial therapy at screening;
  • Subjects with a history of ;
  • Subjects with prior solid organ or bone marrow transplantation;
  • Subjects with current or past history of severe psychiatric disorders;
  • Subjects with severe retinopathy or other severe ophthalmologic diseases;
  • Subjects who have received prohibited study drugs previously or currently;
  • Subjects with concomitant hematological diseases;
  • Subjects with abnormal laboratory findings;
  • Subjects with abnormal interval;
  • Subjects with a history of allergy;
  • Subjects who are breastfeeding or have a positive serum pregnancy test at screening;
  • Subjects participating in another clinical trial, or those who have not completed the specified in the protocol prior to this trial;
  • Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group 1

    Drug: ACT201 Injection

  • Experimental
    Group 2

    Drug: ACT201 Injection

  • Experimental
    Group 3

    Drug: ACT201 Injection

  • Experimental
    Group 4

    Drug: ACT201 Injection

Interventions

  • DrugACT201 Injection

    Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.

    Also known as: Standard of care(PegIFNα-2b Injection)

  • DrugACT201 Injection

    Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.

    Also known as: Standard of care(PegIFNα-2b Injection)

  • DrugACT201 Injection

    Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.

    Also known as: Standard of care(PegIFNα-2b Injection)

  • DrugACT201 Injection

    Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.

06

What researchers measure

Primary outcomes

  1. Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs).

    Time frame: throughout the full study period,an average of 38 weeks

Secondary outcomes

  1. HBsAg, HBsAb and HBV DNA levels and changes from baseline

    Time frame: throughout the full study period,an average of 38 weeks

  2. HBsAg seroclearance rate

    Time frame: throughout the full study period,an average of 38 weeks

  3. HBsAg seroconversion rate

    Time frame: throughout the full study period,an average of 38 weeks

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 10, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Dec 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07929805
Responsible party
Sponsor
First posted
Nov 10, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Xiulan Xue, Ph.D
Contact
xuexiulan2003@126.com
13666061349
Xiulan Xue
principal investigator · The First Affiliated Hospital of Xiamen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion